featured
Design and Baseline Characteristics of the AMPLITUDE-O Cardiovascular Outcomes Trial of Efpeglenatide
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Diabetes, Obesity & Metabolism
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Design and Baseline Characteristics of the AMPLITUDE-O Cardiovascular Outcomes Trial of Efpeglenatide, a Weekly Glucagon-Like Peptide-1 Receptor Agonist
Diabetes Obes Metab 2021 Feb 01;23(2)318-323, HC Gerstein, K Branch, L Heenan, S Del Prato, NS Khurmi, CSP Lam, R Pratley, J Rosenstock, N SattarFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.